At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 734 target
Drug / intervention
Candesartan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Preserved Left Ventricular Systolic Function
In Brief
A Phase 3 clinical trial evaluating Candesartan and Placebo for Congestive Heart Failure. Completed, enrolled 734 participants.
Detailed Summary
A study to evaluate the effect of Atacand on patients with heart failure with preserved left ventricular function
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongestive Heart Failure
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 1999
Primary CompletionMay 2003
First PostedMar 2008
TodayJul 2026
First PostedMar 13, 2008
Enrollment StartJun 1, 1999
Primary CompletionMay 1, 2003
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 18.3 years ago
Interventions
Candesartandrug
Placebodrug